For instance, ISACs bearing TLR7/8/9 agonists activate dendritic cells, enhancing antigen presentation to T cells and, as a consequence, the generation of potent tumor-specific cytotoxic T cell responses, which is required for long-term control of the tumor. The gene discussed is TLR7; the disease is neoplasm.